KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Travere Therapeutics (TVTX) Receivables - Net (2016 - 2025)

Travere Therapeutics' Receivables - Net history spans 12 years, with the latest figure at $80.1 million for Q4 2025.

  • For Q4 2025, Receivables - Net rose 195.52% year-over-year to $80.1 million; the TTM value through Dec 2025 reached $80.1 million, up 195.52%, while the annual FY2025 figure was $80.1 million, 195.7% up from the prior year.
  • Receivables - Net reached $80.1 million in Q4 2025 per TVTX's latest filing, down from $83.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $83.0 million in Q3 2025 to a low of $11.9 million in Q2 2021.
  • Average Receivables - Net over 5 years is $26.4 million, with a median of $20.8 million recorded in 2023.
  • Peak YoY movement for Receivables - Net: decreased 27.62% in 2021, then soared 229.76% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $15.9 million in 2021, then grew by 4.6% to $16.6 million in 2022, then increased by 27.23% to $21.2 million in 2023, then grew by 28.03% to $27.1 million in 2024, then skyrocketed by 195.52% to $80.1 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Receivables - Net are $80.1 million (Q4 2025), $83.0 million (Q3 2025), and $38.7 million (Q2 2025).